At Sylvester, every study, trial and insight brought us closer to transforming outcomes for patients with blood cancers. Sylvester researchers led innovation that offers hope.
We are at the forefront of leukemia research, drug development and clinical trials. During the past decade, the leukemia program led more than 50 clinical trials, resulting in FDA approval of three new drugs to treat leukemia or related conditions during the past two years.
Justin Taylor, M.D., an associate professor of hematology, led a study analyzing demographic trends and environmental factors to improve early detection and treatment strategies for older adults, helping care models evolve with the state’s changing population.
Justin Watts, M.D., leukemia section chief, led a clinical study testing new drug combinations for myelodysplastic syndrome (MDS), aiming to improve survival and reduce complications for patients who once had few options.
Robert Levy, Ph.D., a professor of microbiology and immunology, highlighted transplant immunotherapy strategies to reduce relapse and strengthen immune recovery after stem cell transplants, shaping protocols that make transplants safer and more effective.
Principal investigator Terrence Bradley, M.D., an assistant professor of clinical medicine, and Dr. Watts lead a multi-center study of EP31670, a novel, first-in-class oral drug targeting leukemias and solid tumors. This trial continues a journey that began nearly 15 years ago in the lab of Claes Wahlestedt, M.D., Ph.D., director of the University of Miami Center for Therapeutic Innovation.
A Sylvester clinical trial helped establish a new treatment protocol for multiple myeloma, improving survival rates and setting a benchmark for care worldwide. Findings were presented by researcher C. Ola Landgren, M.D., Ph.D., director of Sylvester Myeloma Institute and co-leader of Translational and Clinical Oncology, at the annual meeting of the American Society of Clinical Oncology.
Mikkael Sekeres, M.D., M.S., Sylvester’s chief of the Division of Hematology, linked Agent Orange exposure to myelodysplastic syndrome, advancing understanding of environmental risk factors and informing prevention strategies while supporting veterans and others affected by toxic exposures.